Cargando…
The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies
The worldwide outbreak of SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 as a novel human coronavirus, was the worrying news at the beginning of 2020. Since its emergence complicated more than 870,000 individuals and led to more than 43,000 deaths worldwide. Considering to the potential...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522676/ https://www.ncbi.nlm.nih.gov/pubmed/33429331 http://dx.doi.org/10.1016/j.intimp.2020.107051 |
_version_ | 1783588235599937536 |
---|---|
author | Molaei, Soheila Dadkhah, Masoomeh Asghariazar, Vahid Karami, Chiman Safarzadeh, Elham |
author_facet | Molaei, Soheila Dadkhah, Masoomeh Asghariazar, Vahid Karami, Chiman Safarzadeh, Elham |
author_sort | Molaei, Soheila |
collection | PubMed |
description | The worldwide outbreak of SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 as a novel human coronavirus, was the worrying news at the beginning of 2020. Since its emergence complicated more than 870,000 individuals and led to more than 43,000 deaths worldwide. Considering to the potential threat of a pandemic and transmission severity of it, there is an urgent need to evaluate and realize this new virus’s structure and behavior and the immunopathology of this disease to find potential therapeutic protocols and to design and develop effective vaccines. This disease is able to agitate the response of the immune system in the infected patients, so ARDS, as a common consequence of immunopathological events for infections with Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV, and SARS-CoV-2, could be the main reason for death. Here, we summarized the immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2 and therapeutic and prophylactic strategies with a focus on vaccine development and its challenges. |
format | Online Article Text |
id | pubmed-7522676 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75226762020-09-29 The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies Molaei, Soheila Dadkhah, Masoomeh Asghariazar, Vahid Karami, Chiman Safarzadeh, Elham Int Immunopharmacol Article The worldwide outbreak of SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 as a novel human coronavirus, was the worrying news at the beginning of 2020. Since its emergence complicated more than 870,000 individuals and led to more than 43,000 deaths worldwide. Considering to the potential threat of a pandemic and transmission severity of it, there is an urgent need to evaluate and realize this new virus’s structure and behavior and the immunopathology of this disease to find potential therapeutic protocols and to design and develop effective vaccines. This disease is able to agitate the response of the immune system in the infected patients, so ARDS, as a common consequence of immunopathological events for infections with Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV, and SARS-CoV-2, could be the main reason for death. Here, we summarized the immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2 and therapeutic and prophylactic strategies with a focus on vaccine development and its challenges. Published by Elsevier B.V. 2021-03 2020-09-29 /pmc/articles/PMC7522676/ /pubmed/33429331 http://dx.doi.org/10.1016/j.intimp.2020.107051 Text en © 2020 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Molaei, Soheila Dadkhah, Masoomeh Asghariazar, Vahid Karami, Chiman Safarzadeh, Elham The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies |
title | The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies |
title_full | The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies |
title_fullStr | The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies |
title_full_unstemmed | The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies |
title_short | The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies |
title_sort | immune response and immune evasion characteristics in sars-cov, mers-cov, and sars-cov-2: vaccine design strategies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522676/ https://www.ncbi.nlm.nih.gov/pubmed/33429331 http://dx.doi.org/10.1016/j.intimp.2020.107051 |
work_keys_str_mv | AT molaeisoheila theimmuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies AT dadkhahmasoomeh theimmuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies AT asghariazarvahid theimmuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies AT karamichiman theimmuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies AT safarzadehelham theimmuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies AT molaeisoheila immuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies AT dadkhahmasoomeh immuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies AT asghariazarvahid immuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies AT karamichiman immuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies AT safarzadehelham immuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies |